153 related articles for article (PubMed ID: 36620927)
1. Value of Preoperative Systemic Immune-Inflammation Index and Albumin-Bilirubin Grade in Patients with Hepatocellular Carcinoma Undergoing Transarterial Embolization.
Ha F; Wang X; Han T; Jia K; Wang S; Song D
Turk J Gastroenterol; 2023 Apr; 34(4):413-420. PubMed ID: 36620927
[TBL] [Abstract][Full Text] [Related]
2. Predictive Outcomes Using Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Akarapatima K; Chang A; Prateepchaiboon T; Pungpipattrakul N; Songjamrat A; Pakdeejit S; Rattanasupar A; Piratvisuth T
J Gastrointest Cancer; 2022 Dec; 53(4):1006-1013. PubMed ID: 34761340
[TBL] [Abstract][Full Text] [Related]
3. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
4. Acute kidney injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy in patients with hepatocellular carcinoma.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Jpn J Clin Oncol; 2020 Jan; 50(1):36-43. PubMed ID: 31665483
[TBL] [Abstract][Full Text] [Related]
5. Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Zhong BY; Ni CF; Ji JS; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Song JJ; Teng GJ
J Vasc Interv Radiol; 2019 Mar; 30(3):330-338. PubMed ID: 30819473
[TBL] [Abstract][Full Text] [Related]
6. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE
J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815
[TBL] [Abstract][Full Text] [Related]
7. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
8. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408
[No Abstract] [Full Text] [Related]
9. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
10. Albumin-Bilirubin Score: An Accurate Predictor of Hepatic Decompensation in High-Risk Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma.
Mohammed MAA; Khalaf MH; Liang T; Wang DS; Lungren MP; Rosenberg J; Kothary N
J Vasc Interv Radiol; 2018 Nov; 29(11):1527-1534.e1. PubMed ID: 30274856
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study.
Jeliazkova P; Umgelter A; Braren R; Kaissis G; Mustafa M; Einwächter H
Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):1036-1041. PubMed ID: 31851090
[TBL] [Abstract][Full Text] [Related]
12. Inversed albumin-to-globulin ratio and underlying liver disease severity as a prognostic factor for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Li J; Li Z; Hao S; Wang J; Chen W; Dai S; Hou Z; Chen B; Zhang Y; Liu D
Diagn Interv Radiol; 2023 May; 29(3):520-528. PubMed ID: 36992824
[TBL] [Abstract][Full Text] [Related]
13. Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization.
Chen HY; Kee KM; Lu SN; Wang JH; Chen CH; Hung CH; Yen YH; Kuo YH
J Formos Med Assoc; 2022 Apr; 121(4):778-786. PubMed ID: 34303584
[TBL] [Abstract][Full Text] [Related]
14. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
[TBL] [Abstract][Full Text] [Related]
16. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
17. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization for treatment of hepatocellular carcinoma: A single center experience.
Idilman I; Peynircioğlu B; Cil BE; Doğanay Erdoğan B; Yalçın S; Bayraktar Y; Kav T; Altundağ K; Balkancı F
Turk J Gastroenterol; 2013; 24(2):141-7. PubMed ID: 23934461
[TBL] [Abstract][Full Text] [Related]
19. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
20. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study.
Lee SK; Song MJ; Kim SH; Park M
PLoS One; 2019; 14(5):e0216173. PubMed ID: 31048923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
